Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Grifols, S.A. has received a consensus rating of "Moderate Buy" from five brokerages, with an average 12-month price objective of $10.30.
• Recent hedge fund activity includes Sequoia Financial Advisors boosting its stake by 14.9% and GAMMA Investing increasing its holdings by 426.1% during the first quarter.
• The company has recently declared a special dividend of $0.1404, with a payout ratio currently at 11.97%.

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) has been given an average rating of "Moderate Buy" by the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $10.30.

GRFS has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Zacks Research raised Grifols to a "hold" rating in a research note on Friday, August 8th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a research note on Monday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th.

Institutional Trading of Grifols

Several large investors have recently modified their holdings of GRFS. Versant Capital Management Inc bought a new stake in shares of Grifols in the first quarter worth about $28,000. Tower Research Capital LLC TRC lifted its holdings in Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after buying an additional 6,335 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock worth $74,000 after buying an additional 4,604 shares during the period. First Trust Advisors LP purchased a new stake in Grifols in the fourth quarter worth about $75,000. Finally, Ballentine Partners LLC purchased a new stake in Grifols in the first quarter worth about $77,000.

Grifols Trading Down 1.6%

Shares of NASDAQ:GRFS traded down $0.16 on Tuesday, reaching $9.88. 359,935 shares of the company traded hands, compared to its average volume of 487,833. The business's 50-day simple moving average is $10.09 and its 200 day simple moving average is $8.65. Grifols has a 52 week low of $6.19 and a 52 week high of $11.14. The stock has a market capitalization of $6.79 billion, a P/E ratio of 8.44, a price-to-earnings-growth ratio of 0.34 and a beta of 0.64. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20.

Grifols Dividend Announcement

The firm also recently announced a special dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's dividend payout ratio (DPR) is presently 11.97%.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.